Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Duality Advisers LP

Posted by Defense World Staff on Sep 20th, 2023

Duality Advisers LP lessened its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 54.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 33,811 shares of the biotechnology company’s stock after selling 41,198 shares during the period. Duality Advisers LP’s holdings in Ironwood Pharmaceuticals were worth $356,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in IRWD. Natixis purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $30,000. Signaturefd LLC increased its holdings in shares of Ironwood Pharmaceuticals by 778.9% in the 1st quarter. Signaturefd LLC now owns 3,173 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 2,812 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $37,000. Lazard Asset Management LLC purchased a new position in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $78,000. Finally, Captrust Financial Advisors increased its holdings in shares of Ironwood Pharmaceuticals by 563.0% in the 2nd quarter. Captrust Financial Advisors now owns 8,188 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 6,953 shares in the last quarter.

Ironwood Pharmaceuticals Trading Up 7.5 %

NASDAQ:IRWD opened at $9.26 on Wednesday. The firm has a 50-day moving average price of $9.79 and a two-hundred day moving average price of $10.37. Ironwood Pharmaceuticals, Inc. has a twelve month low of $8.07 and a twelve month high of $12.66. The company has a market capitalization of $1.44 billion, a P/E ratio of -1.53 and a beta of 0.96.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The business had revenue of $107.38 million during the quarter, compared to the consensus estimate of $103.46 million. Ironwood Pharmaceuticals had a negative net margin of 214.68% and a positive return on equity of 55.17%. On average, equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.28 earnings per share for the current year.

Insider Transactions at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany purchased 36,072 shares of the stock in a transaction dated Friday, September 15th. The stock was acquired at an average cost of $8.32 per share, for a total transaction of $300,119.04. Following the completion of the acquisition, the chief financial officer now directly owns 188,730 shares in the company, valued at approximately $1,570,233.60. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 13.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IRWD. TheStreet downgraded shares of Ironwood Pharmaceuticals from a “b-” rating to a “d-” rating in a report on Tuesday, August 8th. Piper Sandler raised their target price on shares of Ironwood Pharmaceuticals from $16.00 to $19.00 in a report on Tuesday, May 23rd. Finally, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th.

Check Out Our Latest Stock Analysis on Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Company Profile

(Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries.